KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Sales and Divestitures (2018 - 2020)

Aquestive Therapeutics has reported Gains from Sales and Divestitures over the past 3 years, most recently at $64000.0 for Q4 2020.

  • For Q4 2020, Gains from Sales and Divestitures fell 48.8% year-over-year to $64000.0; the TTM value through Dec 2020 reached $64000.0, down 48.8%, while the annual FY2020 figure was $64000.0, 48.8% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2020 was $64000.0 at Aquestive Therapeutics, roughly flat from $64000.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $125000.0 in Q4 2019 and troughed at $29802.0 in Q3 2018.
  • A 3-year average of $61680.2 and a median of $60000.0 in 2018 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 218.77% in 2019 and later tumbled 48.8% in 2020.
  • Year by year, Gains from Sales and Divestitures stood at $60000.0 in 2018, then skyrocketed by 108.33% to $125000.0 in 2019, then tumbled by 48.8% to $64000.0 in 2020.
  • Business Quant data shows Gains from Sales and Divestitures for AQST at $64000.0 in Q4 2020, $64000.0 in Q3 2020, and $60000.0 in Q2 2020.